What is HC Wainwright’s Forecast for Liquidia Q3 Earnings?

Liquidia Corporation (NASDAQ:LQDA) – Equities research analysts at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for Liquidia in a report released on Friday, October 2nd. HC Wainwright analyst A. Fein now forecasts that the company will earn $0.76 per share for the quarter, down from their prior forecast of $1.01. HC Wainwright has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Liquidia’s current full-year earnings is $2.10 per share. HC Wainwright also issued estimates for Liquidia’s Q4 2026 earnings at $0.70 EPS, FY2026 earnings at $2.72 EPS, FY2027 earnings at $4.00 EPS, FY2028 earnings at $4.49 EPS, FY2029 earnings at $5.29 EPS and FY2030 earnings at $6.14 EPS.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The firm had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. During the same period last year, the firm earned ($0.49) EPS. The company’s revenue for the quarter was up 1842.1% on a year-over-year basis.

Several other brokerages have also issued reports on LQDA. Wedbush set a $58.00 target price on Liquidia in a research note on Friday, October 2nd. Piper Sandler set a $129.00 price target on shares of Liquidia in a research note on Friday, July 24th. Jefferies Financial Group raised shares of Liquidia to a “strong-buy” rating in a research note on Thursday, October 1st. Needham & Company LLC cut their price objective on shares of Liquidia from $110.00 to $72.00 and set a “buy” rating for the company in a research note on Thursday, October 1st. Finally, Weiss Ratings upgraded shares of Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Liquidia has a consensus rating of “Hold” and an average target price of $83.69.

Liquidia Stock Performance

Shares of NASDAQ LQDA opened at $26.68 on Tuesday. The stock has a market cap of $2.39 billion, a price-to-earnings ratio of 19.47 and a beta of 0.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. Liquidia has a 1-year low of $21.94 and a 1-year high of $93.61. The stock’s 50-day moving average is $68.07 and its 200 day moving average is $61.99.

Institutional Investors Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LQDA. Globeflex Capital L P bought a new stake in Liquidia in the 2nd quarter worth $175,000. Nykredit A S bought a new position in shares of Liquidia during the second quarter valued at about $177,000. Fluent Financial LLC bought a new position in shares of Liquidia during the second quarter valued at about $287,000. WINTON GROUP Ltd purchased a new stake in shares of Liquidia during the second quarter worth about $335,000. Finally, Fulcrum Equity Management purchased a new stake in shares of Liquidia during the second quarter worth about $399,000. 64.54% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Liquidia news, insider Jason Adair sold 73,631 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $69.09, for a total value of $5,087,165.79. Following the completion of the sale, the insider owned 174,606 shares in the company, valued at approximately $12,063,528.54. The trade was a 29.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Roger Jeffs sold 35,249 shares of the stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $2,520,655.99. Following the sale, the chief executive officer directly owned 1,130,426 shares of the company’s stock, valued at approximately $80,836,763.26. This trade represents a 3.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 757,996 shares of company stock worth $46,429,005. 25.60% of the stock is currently owned by corporate insiders.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $58 price target, well above recent trading levels. The firm continues to project long-term profitability, including estimated EPS of $2.72 in fiscal 2026 and $6.14 in fiscal 2030. HC Wainwright estimates
• Positive Sentiment: An analysis argued that Liquidia could be approximately 74% undervalued, suggesting substantial upside if the company resolves uncertainty surrounding access to YUTREPIA and successfully commercializes the product. Liquidia valuation analysis
• Neutral Sentiment: HC Wainwright reduced its EPS forecasts across 2026–2030, including cuts to fiscal 2026 EPS from $3.44 to $2.72 and fiscal 2030 EPS from $10.08 to $6.14. However, the analyst retained the Buy rating and $58 target, indicating lower estimates but continued confidence in the longer-term story. HC Wainwright estimate revisions
• Negative Sentiment: Director Stephen Bloch sold 235,477 shares worth approximately $6.39 million at an average price of $27.13. A sizable insider sale can pressure sentiment because it may be interpreted as reduced confidence or simply portfolio diversification. SEC insider sale filing
• Negative Sentiment: Two law firms announced shareholder investigations into potential securities claims involving Liquidia. These announcements are often solicitation-driven, but they add litigation overhang and could increase uncertainty for investors. Liquidia investigation alert Shareholder investigation notice

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).